Drug intelligence / Profile preview

coblopasvir

Development stage: Phase 3
Lead developer: Kawin Technology
Modality: Small Molecules
Administration: Oral

Overview

Coblopasvir is a small molecule antiviral drug developed for the treatment of chronic hepatitis C virus (HCV) infection. It acts as an NS5A inhibitor, specifically targeting the nonstructural protein 5A of HCV to inhibit viral replication and assembly. Coblopasvir is used in combination with sofosbuvir for the treatment of chronic HCV genotypes 1, 2, 3, and 6 in adults who are treatment-naïve or have previously received interferon-based therapy, including those with compensated cirrhosis[7][3][4]. The drug was developed by Beijing Kawin Technology Share-Holding and has been approved in China through a priority review process[7][3].

Brand names: 凯力唯Kailiwei
Other names: coblopasvir hydrochlorideKW-136 hydrochlorideKW136 hydrochlorideKW 136 hydrochloride

Targets

NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))

Beyond the preview

Go deeper on coblopasvir.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on coblopasvir.